<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">8501884</journal-id><journal-id journal-id-type="pubmed-jr-id">5061</journal-id><journal-id journal-id-type="nlm-ta">J Perinatol</journal-id><journal-id journal-id-type="iso-abbrev">J Perinatol</journal-id><journal-title-group><journal-title>Journal of perinatology : official journal of the California Perinatal Association</journal-title></journal-title-group><issn pub-type="ppub">0743-8346</issn><issn pub-type="epub">1476-5543</issn></journal-meta><article-meta><article-id pub-id-type="pmid">24503911</article-id><article-id pub-id-type="pmc">3969774</article-id><article-id pub-id-type="doi">10.1038/jp.2014.12</article-id><article-id pub-id-type="manuscript">NIHMS553843</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Evaluating Retinopathy of Prematurity Screening Guidelines for 24-27 Week Gestational Age Infants</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kennedy</surname><given-names>Kathleen A.</given-names></name><degrees>MD MPH</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wrage</surname><given-names>Lisa A.</given-names></name><degrees>MPH</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Higgins</surname><given-names>Rosemary D.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Finer</surname><given-names>Neil N.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Carlo</surname><given-names>Waldemar A.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Walsh</surname><given-names>Michele C.</given-names></name><degrees>MD MS</degrees><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Laptook</surname><given-names>Abbot R.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Faix</surname><given-names>Roger G.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Yoder</surname><given-names>Bradley A.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Schibler</surname><given-names>Kurt</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Gantz</surname><given-names>Marie G.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Das</surname><given-names>Abhik</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Newman</surname><given-names>Nancy S.</given-names></name><degrees>RN</degrees><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Phelps</surname><given-names>Dale L.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><collab>the SUPPORT Study Group of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network</collab></contrib></contrib-group><aff id="A1"><label>1</label> Department of Pediatrics, University of Texas Medical School at Houston, Houston, TX</aff><aff id="A2"><label>2</label> RTI International, Research Triangle Park, NC</aff><aff id="A3"><label>3</label><italic>Eunice Kennedy Shriver</italic> National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD</aff><aff id="A4"><label>4</label> University of California at San Diego, San Diego, CA</aff><aff id="A5"><label>5</label>Division of Neonatology, University of Alabama at Birmingham, Birmingham, AL</aff><aff id="A6"><label>6</label> Department of Pediatrics, Rainbow Babies &#x00026; Children's Hospital, Case Western Reserve University, Cleveland, OH</aff><aff id="A7"><label>7</label> Department of Pediatrics, Women &#x00026; Infants Hospital, Brown University, Providence, RI</aff><aff id="A8"><label>8</label> Department of Pediatrics, Division of Neonatology, University of Utah School of Medicine, Salt Lake City, UT</aff><aff id="A9"><label>9</label> Department of Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH</aff><aff id="A10"><label>10</label> RTI International, Rockville, MD</aff><aff id="A11"><label>11</label> Department of Pediatrics, University of Rochester Medical Center, Rochester, NY</aff><author-notes><corresp id="CR1"><bold>Address correspondence to:</bold> Kathleen A. Kennedy, MD, MPH Richard W. Mithoff Professor of Pediatrics UT-Houston Medical School 6431 Fannin, Suite 2.106 Houston, TX 77030 713 500-6708 FAX: 713 500-0519 <email>Kathleen.A.Kennedy@uth.tmc.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>14</day><month>3</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>06</day><month>2</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>10</month><year>2014</year></pub-date><volume>34</volume><issue>4</issue><fpage>311</fpage><lpage>318</lpage><!--elocation-id from pubmed: 10.1038/jp.2014.12--><permissions><license><license-p>Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:
<uri xlink:type="simple" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p></license></permissions><abstract><sec id="S1"><title>Objective</title><p id="P1">To determine if current retinopathy of prematurity screening guidelines<sup><xref rid="R1" ref-type="bibr">1</xref></sup> adequately identify treatable ROP in a contemporary cohort of extremely low gestation infants.</p></sec><sec id="S2"><title>Study Design</title><p id="P2">Data from the Surfactant, Positive Pressure, and Pulse Oximetry Randomized Trial were used. Inborn infants 24 <sup>0</sup>/<sub>7</sub> to 27 <sup>6</sup>/<sub>7</sub> weeks gestational age with consent prior to delivery were enrolled in 2005-2009. Severe retinopathy of prematurity (Type 1 retinopathy of prematurity or treatment with laser, cryotherapy, or bevacizumab) or death was the primary outcome for the randomized trial. Examinations followed then current American Academy of Pediatrics (AAP) screening recommendations, beginning by 31-33 weeks postmenstrual age.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup></p></sec><sec id="S3"><title>Results</title><p id="P3">1316 infants were enrolled in the trial. 997 of the 1121 who survived to first eye exam had final retinopathy of prematurity outcome determined. 137 (14% of 997) met criteria for severe retinopathy of prematurity and 128 (93%) of those had sufficient data (without missing or delayed exams) to determine age of onset of severe retinopathy of prematurity. Postmenstrual age at onset was 32.1 to 53.1 wks. In this referral center cohort, 1.4% (14/997) developed severe retinopathy of prematurity after discharge.</p></sec><sec id="S4"><title>Conclusion</title><p id="P4">Our contemporary data support the 2013 AAP screening guidelines for ROP for infants 24 <sup>0</sup>/<sub>7</sub> to 27 <sup>6</sup>/<sub>7</sub> weeks gestational age.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Some infants do not meet treatment criteria until after discharge home. Post-discharge follow-up of infants who are still at risk for severe ROP is crucial for timely detection and treatment.</p></sec></abstract><kwd-group><kwd>extremely premature infant</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S5"><title>Introduction</title><p id="P5">Timely detection of treatable retinopathy of prematurity (ROP) is necessary to optimize outcomes for infants who meet the current criteria for treatment. The most recently published screening guidelines<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup> are based on natural history data from the CRYO-ROP<sup><xref rid="R5" ref-type="bibr">5</xref></sup> and LIGHT-ROP<sup><xref rid="R6" ref-type="bibr">6</xref></sup> studies. The CRYO-ROP study<sup><xref rid="R7" ref-type="bibr">7</xref></sup> remains the most carefully conducted analysis of the incidence and timing of the onset of ROP, but it was conducted over 20 years ago (1986-1987). The LIGHT-ROP trial enrolled infants from 1995-1997.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> Over the past two decades, survival of lower birth weight infants in the US and other developed countries has increased.<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> For infants 501-750 g birth weight, survival increased from 41% in 1990-1991 to 55% in 1997-2002.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> The timing of onset of ROP is related to both gestational age (GA) and chronological (postnatal) age.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> It rarely occurs before 30 weeks postmenstrual age (PMA, sum of GA at birth and chronological age) or before 4 weeks chronological age. Current American Academy of Pediatrics (AAP) / American Academy of Ophthalmology (AAO) / American Association of Pediatric Ophthalmology and Strabismus (AAPOS) recommendations are for screening to begin by 31 weeks PMA for infants born at 22-27 weeks.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> The impact of increased survival of extremely low birth weight (ELBW) infants on the incidence and timing of the onset and regression of ROP has not been systematically evaluated.</p><p id="P6">In the CRYO-ROP and LIGHT-ROP studies, treatment was initiated for threshold ROP (now termed &#x0201c;CRYO-ROP threshold&#x0201d;). In the CRYO-ROP study, the earliest identification of CRYO-ROP threshold disease was 32.6 weeks postmenstrual age.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> Based on the results of the ET-ROP trial, treatment is now recommended for Type 1 ROP, defined as stage 3 in zone I or plus disease with any ROP in zone I, or stage 2 or 3 with plus disease in zone II.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> Since Type 1 ROP occurs earlier in the course than CRYO-ROP threshold ROP, it is important to determine if screening criteria developed for CRYO-ROP threshold ROP are still appropriate for reliable timely identification of Type 1 ROP. There have been several more recent publications of the incidence and timing of ROP onset. The ET-ROP trial<sup><xref rid="R12" ref-type="bibr">12</xref></sup> and a population-based cohort study of infants born 2004-2007 in Sweden<sup><xref rid="R13" ref-type="bibr">13</xref></sup> reported the age of onset of stages 1, 2, and 3 ROP; however, the age distribution of onset of Type 1 ROP was not reported in either publication. A recent publication from Canada reported the age of onset of Type 1 ROP in a cohort of 214 infants &#x02264; 27 weeks gestation;<sup><xref rid="R14" ref-type="bibr">14</xref></sup> this cohort included only 24 infants with Type 1 ROP. A recent publication from a German cohort<sup><xref rid="R15" ref-type="bibr">15</xref></sup> reported that &#x0201c;No preterm infants required treatment before the 33rd postmenstrual week or 8th postnatal week, respectively&#x0201d;; the age distribution was not reported. We need updated information about the evolution of ROP in a large contemporary cohort to determine when screening must be initiated to capture all infants as Type 1 ROP develops. Type 2 ROP (stage 1 or 2 ROP without plus disease in Zone I, or stage 3 ROP without plus disease in Zone II) is less severe but warrants close follow up for possible progression to Type 1 ROP. Therefore we also looked at the age of onset of Type 2 ROP.</p><p id="P7">In addition to information about when screening should begin, clinicians need information about when an infant is no longer at risk for severe ROP so that appropriate follow-up can be arranged (particularly for infants who are ready to be discharged from the hospital) or attempts to arrange follow-up can be curtailed. In the CRYO-ROP study, 99% of the infants who reached the CRYO-ROP threshold criteria had done so by 45.9 weeks postmenstrual age.</p><p id="P8">This analysis was designed to describe the natural history of ROP in a recent cohort (born 2005-2009) of inborn infants 24-27 <sup>6</sup>/<sub>7</sub> weeks gestational age who were enrolled in the NICHD Surfactant, Positive Pressure, and Pulse Oximetry Randomized Trial (SUPPORT)<sup><xref rid="R16" ref-type="bibr">16</xref></sup> to determine if the current ROP screening guidelines are still appropriate for timely identification of Type 1 ROP in a contemporary cohort of infants.</p></sec><sec sec-type="methods" id="S6"><title>Methods</title><p id="P9">In the SUPPORT trial conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network, severe ROP [defined as Type 1 ROP or treatment with laser ablation, cryotherapy, bevacizumab (monoclonal antibody to vascular endothelial growth factor) injection, scleral buckle, or vitrectomy] or death before discharge was the primary outcome for the O<sub>2</sub> saturation target arm of the factorial design trial. ROP outcome data were prospectively collected for all enrolled infants.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> Inborn infants 24 <sup>0</sup>/<sub>7</sub> &#x02013; 27 <sup>6</sup>/<sub>7</sub> weeks gestation (no birth weight limits) were eligible for this trial if prenatal consent was obtained, there were no known congenital malformations, and full resuscitation was planned. Study eye examinations were performed by each site's examining ophthalmologists using the International Classification of ROP.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> Ophthalmology exams began no later than 31-33 weeks postmenstrual age, as recommended in the AAP/AAO/AAPOS guidelines that were in place when the study began.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup> Subsequent inpatient and outpatient exams were conducted according to the ophthalmologists&#x02019; established screening procedures at each center, based on the findings of the previous examination. The following data were recorded for each eye at each exam: the date of the eye exam, the highest stage of ROP in the lowest zone, the highest stage of ROP in any zone, the presence of plus disease, and whether the infant met the criteria for Type 1 ROP. Study eye exam data were recorded for each exam until one of the study endpoints: death; severe ROP (Type 1 or worse ROP or ROP first treated with peripheral retinal ablation, vitreoretinal surgery or bevacizumab injection as detailed above) in either eye; or no severe ROP (full vascularization to the ora serrata or vascularization in zone III (without severe ROP) on 2 consecutive exams. Examinations required for the study (including exams after hospital discharge) were curtailed at 55 wks PMA.</p><p id="P10">Postmenstrual age was calculated as gestational age at birth (weeks+days using the best obstetrical estimate) plus the chronological age in weeks+days at the time of each exam. For this observational study, &#x0201c;age of onset&#x0201d; was defined as the postmenstrual or chronological age at which ROP or ROP of a given severity was detected, with the recognition that onset was some time interval prior to detection. Infants with Type 1 ROP whose first exam with Type 1 ROP was preceded by a gap of more than 2 weeks (or more than 1 week if the previous exam had ROP in zone I) between exams were defined as having an uncertain age of onset. No infants had Type 1 ROP on the initial exam. Infants who did not complete exams according to the study schedule (adjudicated ROP outcomes) were not included in this observational study. In cases where the findings differed between eyes, the age of onset was recorded as the earliest age at which the ROP criteria were met in either eye.</p><p id="P11">Categorical outcomes were compared using Chi square tests; continuous outcomes were compared using t-tests or Wilcoxon tests where appropriate. Non-parametric confidence limits are provided for continuous data grouped into quantiles.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> Cumulative incidence curves for age of onset of severe ROP and age of maturity were compared by gestational age subgroups (26-27 weeks vs 24-25 weeks) using Kolmogorov-Smirnov tests. All analyses were performed using SAS v. 9.2 (SAS Institute, Cary, NC).</p></sec><sec sec-type="results" id="S7"><title>Results</title><p id="P12">1316 infants were enrolled in the SUPPORT trial from 2005-2009 and 1091 survived to ROP determination (<xref ref-type="fig" rid="F1">Figure 1</xref>). Among infants who survived to ROP determination, 91% (997/1091) had a definitive ROP outcome; 94 of the ROP outcomes were adjudicated. Sixty-four percent (643/997) of these infants developed ROP and 14% (137/997) developed severe ROP. Among infants with severe ROP, 93% (128/137) had sufficient data (no missing or delayed exams prior to &#x0201c;onset&#x0201d; exam) to determine the age of onset of ROP.</p><p id="P13">The baseline demographic characteristics of the infants with and without various ROP categories are shown in <xref ref-type="table" rid="T1">Table 1</xref>. As expected, infants with ROP were lower birth weight and more frequently non-Hispanic White as compared to infants without ROP. The risk of ROP by gestational age, in this cohort, is depicted in <xref ref-type="fig" rid="F2">Figure 2</xref>. As expected, the likelihood of having no ROP increased and the likelihood of having severe ROP decreased with each increasing week of completed gestation at birth (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p><p id="P14">Several previously reported risk factors for ROP are shown in <xref ref-type="table" rid="T2">Table 2</xref>.<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> Consistent with prior observational studies, as compared to infants without ROP, infants with ROP had a longer duration of supplemental oxygen and more frequently had late onset sepsis, fungal sepsis, intraventricular hemorrhage, necrotizing enterocolitis, and patent ductus arteriosus (p&#x0003c;0.05 for all comparisons of no ROP vs any ROP).</p><p id="P15">For infants who had any stage of ROP and had a known age of onset, the cumulative distribution for the age of onset is displayed in <xref ref-type="table" rid="T3">Table 3</xref>. Of note, 6.4 weeks was the minimum (youngest) chronologic age at which severe ROP was seen; 95% of cases had occurred by 17 weeks chronologic age. Also, 25% of severe ROP was identified after 38.6 weeks postmenstrual age and 5% was identified after 43.3 weeks. For the 9 infants with severe ROP and uncertain age of onset, the age of identification ranged from 33.7-40.0 weeks PMA. For the 64 infants who had an exam with Type II ROP prior to the first exam with Type I ROP (and known time of onset for both), the interval between these observations ranged from 0.1 to 17.9 weeks [median (IQR) 1.9 (0.9-3.0) weeks]. There were also 85 infants who had Type II ROP that regressed and 64 infants who developed Type I ROP without have a prior exam that met the criteria for Type II. The distributions for onset of ROP were examined separately (not shown) for infants in each of the treatment arms (lower oxygen saturation and higher oxygen saturation target ranges) and the distributions were similar so only the combined data are shown. The distributions for age of onset of severe ROP for each two-week interval of completed gestation at birth are shown in <xref ref-type="fig" rid="F3">Figure 3</xref>. In contrast to prior studies,<sup><xref rid="R5" ref-type="bibr">5</xref></sup> our data did not show an inverse relationship between gestational age at birth and chronological age at onset of treatable ROP. PMA of onset of severe ROP is significantly later for GA groups 26-27 weeks vs. 24-25 weeks (p&#x0003c;0.01). There is no significant difference in the distribution of chronologic age of onset between these two GA groups.</p><p id="P16">The age at which the retinal vessels matured to the point of minimal risk of progression to severe ROP (to the ora serrata or two consecutive exams with vessels in zone III without stage 3 or plus disease) is shown in <xref ref-type="fig" rid="F4">Figure 4</xref> for infants who never had ROP and for infants who had mild or moderate ROP (ROP that did not meet criteria for severe ROP). The cumulative distributions are shown by postmenstrual age and by chronological age, plotted separately for each completed week of gestation at birth. Among infants who had one exam with vessels recorded as in Zone III (but not to the ora serrata), 2/251 infants subsequently developed severe ROP. Retinal vessels reached final favorable status several weeks later in infants with mild or moderate ROP as compared to infants who never had ROP. The distributions of PMA and chronologic age at maturity were significantly different for infants with mild/moderate ROP vs. infants with no ROP, both overall and within GA groups (p&#x0003c; .0001).</p><p id="P17">The proportions of infants who had severe (Type 1 or treated) ROP identified after discharge home are shown in <xref ref-type="table" rid="T4">Table 4</xref>. Infants with severe ROP identified after discharge had onset of ROP at a later postmenstrual age and were discharged at an earlier postmenstrual age than infants who had severe ROP identified before discharge. In this referral center cohort of 997 infants, 1 infant (0.1%; or 0.7% of 137 infants with severe ROP) was diagnosed with severe ROP after back transfer to a lower acuity neonatal intensive care unit (while still in the hospital); 14 (1.4% of the cohort; or 10% of infants with severe ROP) reached severe ROP after discharge home. Among the 14 infants with severe ROP identified after discharge home, 4 had been transferred to lower acuity neonatal intensive care units prior to discharge home. To explore whether infants at high risk of developing severe ROP after discharge could be identified before discharge, we compared the last pre-discharge exams (<xref ref-type="table" rid="T5">Table 5</xref>) and clinical risk factors (<xref ref-type="table" rid="T6">Table 6</xref>) for infants who did and did not develop severe ROP after discharge (among infants whose exams had not reached final favorable status at the time of discharge). While infants with vessels in Zone I or with ROP in Zone II on the last pre-discharge exam were at the highest risk for developing severe ROP after discharge (1/4=25% and 10/206=5%, respectively), 1 case of severe ROP after discharge (1/82=1%) occurred in an infant with ROP in Zone III on the last exam before discharge. Infants who developed severe ROP after discharge were slightly lower birth weight and lower gestational age and treated with supplemental oxygen longer, but we did not identify any clinical risk factors in our data that clearly identify infants at risk to develop severe ROP after discharge.</p></sec><sec sec-type="discussion" id="S8"><title>Discussion</title><p id="P18">Current screening guidelines are based on studies conducted over 20 years ago. Earlier treatment of ROP has been recommended since 2003,<sup><xref rid="R11" ref-type="bibr">11</xref></sup> so updated information regarding the timing of onset of ROP is needed. While our study findings differ from previous studies<sup><xref rid="R5" ref-type="bibr">5</xref></sup> in that the chronologic age of ROP onset was not later in lower GA infants, our findings still support the 2013 screening guidelines for infants 24-27 6/7 weeks gestation at birth.</p><p id="P19">In the CRYO-ROP natural history study,<sup><xref rid="R5" ref-type="bibr">5</xref></sup> lower birth weight infants developed treatable ROP at a later chronological age than larger infants, such that the incidence curves for birth weight strata were superimposed when plotted by postmenstrual age. This observation led to a recommendation by the AAP/AAO/AAPOS that ROP screening could be delayed until 31 weeks postmenstrual age, regardless of gestational age at birth,<sup><xref rid="R1" ref-type="bibr">1</xref></sup> albeit with a caution that the data supporting the recommendation included very few 22-23 week infants. This relationship (later postnatal onset in lower gestational age infants) was not apparent in our data. There are several potential explanations for this difference. Firstly, the gestational age range of infants in our study was relatively narrow because our cohort was selected by gestational age. The CRYO-ROP cohort was selected by birth weight (&#x02264;1250 g) and therefore included a wider gestational age range and a relatively high proportion (20%) of infants who were small for gestational age.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> Although both the CRYO-ROP and SUPPORT trials used obstetrical criteria, if available, for assigning gestational age, the more recent SUPPORT trial relied more heavily on early ultrasound criteria. If the CRYO-ROP trial more often used pediatric exam criteria, this could have resulted in a systematic overestimate of gestational age<sup><xref rid="R23" ref-type="bibr">23</xref></sup> and in a systematic bias toward more stable lower risk infants having gestational age overestimated. In our data, age of onset was related to chronological age as well as PMA such that onset of severe ROP occurred at a slightly earlier postmenstrual age in more immature infants.</p><p id="P20">The more recent studies of the timing of onset of ROP have had inconsistent findings regarding the relationship of onset with chronologic vs postmenstrual age. In the study by Austeng et al,<sup><xref rid="R13" ref-type="bibr">13</xref></sup> which included 22-26 week GA infants, the more immature infants developed ROP (any ROP) at an earlier PMA than more mature infants. The study by Isaza et al<sup><xref rid="R14" ref-type="bibr">14</xref></sup> included 23-27 week infants; infants &#x02264;25 weeks GA developed any ROP at the same mean PMA (later mean chronologic age) than infants &#x0003e;25 weeks. In this study, the onset of Type 1 ROP occurred at an earlier PMA and at an earlier chronologic age in the less mature infants. In our data, the median age of onset of Type 1 ROP (50% cumulative incidence in <xref ref-type="fig" rid="F3">Figure 3</xref>) occurred at an earlier PMA in the less mature (24-25 week) infants, whereas the medians for chronologic age are similar.</p><p id="P21">For the purpose of screening (not missing cases of treatable ROP), the earliest and latest ages of onset of Type 1 ROP are more important than the mean or median age. We did not observe severe ROP before 6 weeks chronological age or before 32 weeks PMA. These findings are consistent with the other recent studies. In the Canadian study,<sup><xref rid="R14" ref-type="bibr">14</xref></sup> the earliest onset of Type 1 ROP was 6 weeks chronological age or 32.7 weeks PMA. In the study by Muether et al<sup><xref rid="R15" ref-type="bibr">15</xref></sup> that included 767 infants 22-35 weeks gestation, no infants required treatment before 8 weeks chronologic age or 33 weeks PMA. Together these studies provide no evidence that current screening guidelines should be changed to accommodate earlier (Type 1 ROP) treatment, although we still have limited data for 22-23 week GA infants.</p><p id="P22">For clinicians who care for infants in tertiary referral centers, an important question is whether infants are still at risk for treatable ROP when they are otherwise ready to be discharged to home. We have not identified any other studies that report the risk of treatable ROP occurring after discharge home. While it was not a common occurrence in our study (1.4% of the cohort and 14% of the infants with severe ROP), the potential consequences could be severe if infants who are still at risk for treatable ROP are lost to follow up after discharge. We were not able to identify any risk factors or combination of risk factors that would distinguish these infants from others who did not develop Type 1 ROP after discharge.</p><p id="P23">This observational study has several important limitations. We were unable to generate true population incidence data from this cohort because only consented inborn infants were included. This consented enrolled cohort differed from the non-enrolled populations in participating sites in that the proportion receiving antenatal steroids was higher and the proportion of Caucasians was higher.<sup><xref rid="R24" ref-type="bibr">24</xref></sup> The SUPPORT trial inclusion criteria limit the generalizability of these data to infants &#x0003c; 24 weeks gestation who are at even higher risk of ROP or to infants &#x0003e;27 <sup>6</sup>/<sub>7</sub> weeks. The ophthalmology exams for this study were performed by each unit's examining ophthalmologists according to AAP/AAO/AAPOS recommendations using the international classification of ROP but with no formal certification for the study. This might lead to more inconsistency or random error than would occur under strict study exam protocols, but it more closely reflects what typically occurs in clinical practice.</p><p id="P24">Current AAP/AAO/AAPOS screening guidelines, published in 2013,<sup><xref rid="R1" ref-type="bibr">1</xref></sup> recommend that ROP screening should begin by 31 weeks postmenstrual age and continue until vessels have reached zone III for infants without previous zone I or II ROP, until full vascularization to the ora serrata for infants treated with bevacizumab, until 50 weeks postmenstrual age for infants without prethreshold ROP, or until ROP has regressed. In our cohort, the postmenstrual age at onset of severe ROP ranged from 32.1 to 53.1 wks, although only 1 infant developed severe ROP after 45 weeks. Our data therefore do not support a change in the 2013 screening guidelines. In this referral center cohort of 997 infants, 0.1% (0.7% of those with severe ROP) were diagnosed with severe ROP after back transfer to a lower acuity neonatal intensive care unit; 1.4% (10% of infants with severe ROP) reached severe ROP after discharge home. Post-discharge follow-up of infants who are still at risk for severe ROP is crucial for timely detection and treatment.</p><p id="P25">Future population-based studies are needed to better inform the optimal windows for ROP screening in extremely premature infants, particularly those less than 24 weeks and more than 27 weeks gestation at birth. These studies are difficult because they require strict adherence to screening protocols and careful documentation of all eye exams in a large number of infants to identify the full spectrum of age at onset. While randomized trials most often employ such rigorous data collection methods, they are often limited by selection bias that is introduced by the consent process for trials.<sup><xref rid="R24" ref-type="bibr">24</xref></sup></p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>1</label><media xlink:href="NIHMS553843-supplement-1.docx" orientation="portrait" xlink:type="simple" id="d37e608" position="anchor"/></supplementary-material></sec></body><back><ack id="S9"><p><bold>Funding source:</bold> The National Institutes of Health, the <italic>Eunice Kennedy Shriver</italic> National Institute of Child Health and Human Development (NICHD), and the National Heart, Lung, and Blood Institute (NHLBI) provided grant support for the Neonatal Research Network's SUPPORT trial.</p></ack><fn-group><fn id="FN1"><p id="P26"><bold>Conflict of Interest:</bold> The authors declare that they have no financial interests related to the work described in this manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, and American Association of Certified Orthoptists</collab></person-group><article-title>Screening examination of premature infants for retinopathy of prematurity.</article-title><source>Pediatrics</source><year>2013</year><volume>131</volume><fpage>189</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">23277315</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Academy of Pediatrics, American Association for Pediatric Ophthalmology and Strabismus, American Academy of Ophthalmology</collab></person-group><article-title>Screening examination of premature infants for retinopathy of prematurity.</article-title><source>Pediatrics</source><year>2001</year><volume>108</volume><fpage>809</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">11533356</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus</collab></person-group><article-title>Screening examination of premature infants for retinopathy of prematurity.</article-title><source>Pediatrics</source><year>2006</year><volume>117</volume><fpage>572</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">16452383</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jefferies</surname><given-names>A</given-names></name></person-group><article-title>Retinopathy of prematurity: Recommendations for screening.</article-title><source>Paediatr Child Health</source><year>2010</year><volume>15</volume><fpage>667</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">22131866</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>EA</given-names></name><name><surname>Flynn</surname><given-names>JT</given-names></name><name><surname>Hardy</surname><given-names>RJ</given-names></name><name><surname>Phelps</surname><given-names>DL</given-names></name><name><surname>Phillips</surname><given-names>CL</given-names></name><name><surname>Schaffer</surname><given-names>DB</given-names></name><etal/></person-group><article-title>Incidence and early course of retinopathy of prematurity.</article-title><source>Ophthalmology</source><year>1991</year><volume>98</volume><fpage>1628</fpage><lpage>1640</lpage><pub-id pub-id-type="pmid">1800923</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>JD</given-names></name><name><surname>Dobson</surname><given-names>V</given-names></name><name><surname>Quinn</surname><given-names>GE</given-names></name><name><surname>Fielder</surname><given-names>AR</given-names></name><name><surname>Palmer</surname><given-names>EA</given-names></name><name><surname>Saunders</surname><given-names>RA</given-names></name><etal/></person-group><article-title>the CRYOROP and LIGHT-ROP Cooperative Study Groups. Evidence-based screening criteria for retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHT-ROP studies.</article-title><source>Arch Ophthalmol</source><year>2002</year><volume>120</volume><fpage>1470</fpage><lpage>1476</lpage><pub-id pub-id-type="pmid">12427059</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cryotherapy for Retinopathy of Prematurity Cooperative Group</collab></person-group><article-title>Multicenter trial of cryotherapy for retinopathy of prematurity; preliminary results.</article-title><source>Pediatrics</source><year>1988</year><volume>81</volume><fpage>697</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">2895910</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>JD</given-names></name><name><surname>Hardy</surname><given-names>RJ</given-names></name><name><surname>Kennedy</surname><given-names>KA</given-names></name><name><surname>Spencer</surname><given-names>R</given-names></name><name><surname>van Heuven</surname><given-names>WA</given-names></name><name><surname>Fielder</surname><given-names>AR</given-names></name></person-group><article-title>Lack of efficacy of light reduction in preventing retinopathy of prematurity. Light Reduction in Retinopathy of Prematurity (LIGHT-ROP) Cooperative Group.</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><fpage>1572</fpage><lpage>1576</lpage><pub-id pub-id-type="pmid">9603794</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanaroff</surname><given-names>AA</given-names></name><name><surname>Stoll</surname><given-names>BJ</given-names></name><name><surname>Wright</surname><given-names>LL</given-names></name><name><surname>Carlo</surname><given-names>WA</given-names></name><name><surname>Ehrenkranz</surname><given-names>RA</given-names></name><name><surname>Stark</surname><given-names>AR</given-names></name><etal/></person-group><article-title>the NICHD Neonatal Research Network. Trends in neonatal morbidity and mortality for very low birthweight infants.</article-title><source>Am J Ob Gynecol</source><year>2007</year><volume>196</volume><fpage>147</fpage><fpage>e1</fpage><lpage>8</lpage></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoll</surname><given-names>BJ</given-names></name><name><surname>Hansen</surname><given-names>NI</given-names></name><name><surname>Bell</surname><given-names>EF</given-names></name><name><surname>Shankaran</surname><given-names>S</given-names></name><name><surname>Laptook</surname><given-names>AR</given-names></name><name><surname>Walsh</surname><given-names>MC</given-names></name></person-group><article-title>the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network.</article-title><source>Pediatrics</source><year>2010</year><volume>126</volume><fpage>443</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">20732945</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The Early Treatment for Retinopathy of Prematurity Cooperative Group</collab></person-group><article-title>Revised indications for treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.</article-title><source>Arch Ophthalmol</source><year>2003</year><volume>121</volume><fpage>1684</fpage><lpage>1696</lpage><pub-id pub-id-type="pmid">14662586</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Good</surname><given-names>WV</given-names></name><name><surname>Hardy</surname><given-names>RJ</given-names></name><name><surname>Dobson</surname><given-names>V</given-names></name><name><surname>Palmer</surname><given-names>EA</given-names></name><name><surname>Phelps</surname><given-names>DL</given-names></name><name><surname>Quintos</surname><given-names>M</given-names></name><etal/></person-group><article-title>the Early Treatment for Retinopathy of Prematurity Cooperative Group. The incidence and course of retinopathy of prematurity: findings from the Early Treatment for Retinopathy of Prematurity Study.</article-title><source>Pediatrics</source><year>2005</year><volume>116</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15995025</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Austeng</surname><given-names>D</given-names></name><name><surname>Kallen</surname><given-names>KB</given-names></name><name><surname>Hellstrom</surname><given-names>A</given-names></name><name><surname>Tornqvist</surname><given-names>K</given-names></name><name><surname>Holmstrom</surname><given-names>GE</given-names></name></person-group><article-title>Natural history of retinopathy of prematurity in infants born before 27 weeks&#x02019; gestation in Sweden.</article-title><source>Arch Ophthalmol</source><year>2010</year><volume>128</volume><fpage>1289</fpage><lpage>1294</lpage><pub-id pub-id-type="pmid">20937998</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isaza</surname><given-names>G</given-names></name><name><surname>Arora</surname><given-names>S</given-names></name></person-group><article-title>Incidence and severity of retinopathy of prematurity in extremely premature infants.</article-title><source>Can J Ophthalmol</source><year>2012</year><volume>47</volume><fpage>296</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">22687311</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muether</surname><given-names>PS</given-names></name><name><surname>Kribs</surname><given-names>A</given-names></name><name><surname>Hahn</surname><given-names>M</given-names></name><name><surname>Schumacher</surname><given-names>J</given-names></name><name><surname>Eifinger</surname><given-names>F</given-names></name><name><surname>Kirchhof</surname><given-names>B</given-names></name><etal/></person-group><article-title>No advanced retinopathy of prematurity stages 4 or 5 in a large high-risk German cohort.</article-title><source>Br J Ophthalmol</source><year>2012</year><volume>96</volume><fpage>400</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">21719567</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network</collab></person-group><article-title>Target ranges of oxygen saturation in extremely preterm infants.</article-title><source>New Engl J Med</source><year>2010</year><volume>362</volume><fpage>1959</fpage><lpage>1969</lpage><pub-id pub-id-type="pmid">20472937</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Academy of Pediatrics</collab></person-group><article-title>An international classification of retinopathy of prematurity.</article-title><source>Pediatrics</source><year>1984</year><volume>74</volume><fpage>127</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">6547526</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>GJ</given-names></name><name><surname>Meeker</surname><given-names>WQ</given-names></name></person-group><source>Statistical Intervals: A Guide for Practitioners</source><year>1991</year><publisher-name>John Wiley &#x00026; Sons</publisher-name></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>N</given-names></name><name><surname>Clive</surname><given-names>J</given-names></name><name><surname>Bhandari</surname><given-names>V</given-names></name></person-group><article-title>Current incidence of retinopathy of prematurity, 1989-1997.</article-title><source>Pediatrics</source><year>1999</year><volume>104</volume><fpage>e26</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">10469809</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>PM</given-names></name><name><surname>Fang</surname><given-names>PC</given-names></name><name><surname>Huang</surname><given-names>CB</given-names></name><name><surname>Kou</surname><given-names>HK</given-names></name><name><surname>Chung</surname><given-names>MY</given-names></name><name><surname>Yang</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Risk factors of retinopathy of prematurity in premature infants weighing less than 1600 g.</article-title><source>Am J Perinatol</source><year>2005</year><volume>22</volume><fpage>115</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">15731992</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lad</surname><given-names>EM</given-names></name><name><surname>Hernandez-Boussard</surname><given-names>T</given-names></name><name><surname>Morton</surname><given-names>JM</given-names></name><name><surname>Moshfeghi</surname><given-names>DM</given-names></name></person-group><article-title>Incidence of retinopathy of prematurity in the United States: 1997 through 2005.</article-title><source>Am J Ophthalmol</source><year>2009</year><volume>148</volume><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">19541285</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phelps</surname><given-names>DL</given-names></name><name><surname>Brown</surname><given-names>DR</given-names></name><name><surname>Tung</surname><given-names>B</given-names></name><name><surname>Cassady</surname><given-names>G</given-names></name><name><surname>McClead</surname><given-names>RE</given-names></name><name><surname>Purohit</surname><given-names>DM</given-names></name><etal/></person-group><article-title>28-day survival rates of 6676 neonates with birth weights of 1250 grams or less.</article-title><source>Pediatrics</source><year>1991</year><volume>87</volume><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">1984621</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donovan</surname><given-names>EF</given-names></name><name><surname>Tyson</surname><given-names>JE</given-names></name><name><surname>Ehrenkranz</surname><given-names>RA</given-names></name><name><surname>Verter</surname><given-names>J</given-names></name><name><surname>Wright</surname><given-names>LL</given-names></name><name><surname>Korones</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Inaccuracy of Ballard scores before 28 weeks&#x02019; gestation.</article-title><source>J Pediatr</source><year>1999</year><volume>135</volume><fpage>147</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">10431107</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rich</surname><given-names>W</given-names></name><name><surname>Finer</surname><given-names>NN</given-names></name><name><surname>Gantz</surname><given-names>MG</given-names></name><name><surname>Newman</surname><given-names>NS</given-names></name><name><surname>Hensman</surname><given-names>AM</given-names></name><name><surname>Hale</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Enrollment of extremely low birth weight infants in a clinical research study may not be representative.</article-title><source>Pediatrics</source><year>2012</year><volume>129</volume><fpage>480</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">22371462</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsen</surname><given-names>IE</given-names></name><name><surname>Groveman</surname><given-names>SA</given-names></name><name><surname>Lawson</surname><given-names>ML</given-names></name><name><surname>Clark</surname><given-names>RH</given-names></name><name><surname>Zemel</surname><given-names>BS</given-names></name></person-group><article-title>New intrauterine growth curves based on United States data.</article-title><source>Pediatrics</source><year>2010</year><volume>125</volume><fpage>e214</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">20100760</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>MC</given-names></name><name><surname>Kliegman</surname><given-names>RM</given-names></name></person-group><article-title>Necrotizing enterocolitis: treatment based on staging criteria.</article-title><source>Pediatr Clin North Am</source><year>1986</year><volume>33</volume><fpage>179</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">3081865</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow diagram of subjects in the original trial and current analysis</p></caption><graphic xlink:href="nihms-553843-f0001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Risk of ROP by gestational age at birth (in completed weeks) among all SUPPORT trial infants with known outcome (997 survivors + 223 infants who died)</p></caption><graphic xlink:href="nihms-553843-f0002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Postmenstrual and chronological age of onset for severe (Type 1 or treated) ROP (among infants with age of onset determined) by gestational age at birth with 95% confidence intervals (shaded areas)</p></caption><graphic xlink:href="nihms-553843-f0003"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Postmenstrual and chronological age of &#x0201c;favorable outcome&#x0201d; (vessels to the ora serrata or vessels in Zone III on two consecutive exams) by gestational age at birth</p></caption><graphic xlink:href="nihms-553843-f0004"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics of infants in SUPPORT Trial and observational study</p></caption><table frame="box" rules="cols"><thead><tr><th rowspan="3" align="left" valign="top" colspan="1"/><th rowspan="3" align="center" valign="middle" colspan="1">Infants Enrolled in SUPPORT Trial</th><th colspan="4" align="center" valign="top" rowspan="1">Infants Included in Observational Study (Reached Final ROP<sup><xref ref-type="table-fn" rid="TFN1">1</xref></sup> Outcome)<hr/></th></tr><tr><th rowspan="2" align="center" valign="middle" colspan="1">All ROP Outcomes</th><th colspan="3" align="center" valign="top" rowspan="1">By ROP Outcome Category<hr/></th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">No ROP</th><th align="center" valign="top" rowspan="1" colspan="1">Mild/Moderate ROP</th><th align="center" valign="top" rowspan="1" colspan="1">Severe (Type 1 or Treated) ROP</th></tr><tr><th colspan="6" align="center" valign="top" rowspan="1"><hr/></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">n</td><td align="center" valign="top" rowspan="1" colspan="1">1316</td><td align="center" valign="top" rowspan="1" colspan="1">997</td><td align="center" valign="top" rowspan="1" colspan="1">354</td><td align="center" valign="top" rowspan="1" colspan="1">506</td><td align="center" valign="top" rowspan="1" colspan="1">137</td></tr><tr><td colspan="6" align="center" valign="top" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gestational age, wks [mean (SD<sup><xref ref-type="table-fn" rid="TFN2">2</xref></sup>)]</td><td align="center" valign="top" rowspan="1" colspan="1">26.2 (1.1)</td><td align="center" valign="top" rowspan="1" colspan="1">26.3 (1.1)</td><td align="center" valign="top" rowspan="1" colspan="1">26.8 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">26.2 (1.0)</td><td align="center" valign="top" rowspan="1" colspan="1">25.4 (0.9)</td></tr><tr><td colspan="6" align="center" valign="top" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Birth weight, g [mean (SD)]</td><td align="center" valign="top" rowspan="1" colspan="1">830 (193)</td><td align="center" valign="top" rowspan="1" colspan="1">849 (190)</td><td align="center" valign="top" rowspan="1" colspan="1">943 (173)</td><td align="center" valign="top" rowspan="1" colspan="1">823 (180)</td><td align="center" valign="top" rowspan="1" colspan="1">704 (142)</td></tr><tr><td colspan="6" align="center" valign="top" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Small for gestational age<sup><xref ref-type="table-fn" rid="TFN3">3</xref></sup> [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">173 (13)</td><td align="center" valign="top" rowspan="1" colspan="1">117 (12)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (6)</td><td align="center" valign="top" rowspan="1" colspan="1">65 (13)</td><td align="center" valign="top" rowspan="1" colspan="1">30 (22)</td></tr><tr><td colspan="6" align="center" valign="top" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race/ethnicity [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Non-Hispanic Black</td><td align="center" valign="top" rowspan="1" colspan="1">489 (37)</td><td align="center" valign="top" rowspan="1" colspan="1">374 (38)</td><td align="center" valign="top" rowspan="1" colspan="1">154 (44)</td><td align="center" valign="top" rowspan="1" colspan="1">179 (35)</td><td align="center" valign="top" rowspan="1" colspan="1">41 (30)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Non-Hispanic White</td><td align="center" valign="top" rowspan="1" colspan="1">521 (40)</td><td align="center" valign="top" rowspan="1" colspan="1">398 (40)</td><td align="center" valign="top" rowspan="1" colspan="1">125 (35)</td><td align="center" valign="top" rowspan="1" colspan="1">212 (42)</td><td align="center" valign="top" rowspan="1" colspan="1">61 (45)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hispanic</td><td align="center" valign="top" rowspan="1" colspan="1">259 (20)</td><td align="center" valign="top" rowspan="1" colspan="1">190 (19)</td><td align="center" valign="top" rowspan="1" colspan="1">69 (19)</td><td align="center" valign="top" rowspan="1" colspan="1">93 (18)</td><td align="center" valign="top" rowspan="1" colspan="1">28 (20)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Other</td><td align="center" valign="top" rowspan="1" colspan="1">47 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">35 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (2)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (5)</td></tr><tr><td colspan="6" align="center" valign="top" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">712 (54)</td><td align="center" valign="top" rowspan="1" colspan="1">529 (53)</td><td align="center" valign="top" rowspan="1" colspan="1">195 (55)</td><td align="center" valign="top" rowspan="1" colspan="1">256 (51)</td><td align="center" valign="top" rowspan="1" colspan="1">78 (57)</td></tr><tr><td colspan="6" align="center" valign="top" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Antenatal steroids [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">1265 (96)</td><td align="center" valign="top" rowspan="1" colspan="1">955 (96)</td><td align="center" valign="top" rowspan="1" colspan="1">341 (96)</td><td align="center" valign="top" rowspan="1" colspan="1">480 (95)</td><td align="center" valign="top" rowspan="1" colspan="1">134 (98)</td></tr><tr><td colspan="6" align="center" valign="top" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Multiple birth [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">337 (26)</td><td align="center" valign="top" rowspan="1" colspan="1">253 (25)</td><td align="center" valign="top" rowspan="1" colspan="1">91 (26)</td><td align="center" valign="top" rowspan="1" colspan="1">121 (24)</td><td align="center" valign="top" rowspan="1" colspan="1">41 (30)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>1</label><p id="P27">Retinopathy of prematurity</p></fn><fn id="TFN2"><label>2</label><p id="P28">Standard deviation</p></fn><fn id="TFN3"><label>3</label><p id="P29">Based on Olsen<sup>25</sup> growth curves</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Risk factors for ROP<sup><xref ref-type="table-fn" rid="TFN4">1</xref></sup></p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Risk Factor</th><th align="center" valign="top" rowspan="1" colspan="1">No ROP<sup><xref ref-type="table-fn" rid="TFN5">2</xref></sup></th><th align="center" valign="top" rowspan="1" colspan="1">Any ROP (Mild, Moderate, or Severe)</th><th align="center" valign="top" rowspan="1" colspan="1">Mild/Moderate ROP</th><th align="center" valign="top" rowspan="1" colspan="1">Severe (Treated or Type 1) ROP</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">n</td><td align="center" valign="top" rowspan="1" colspan="1">354</td><td align="center" valign="top" rowspan="1" colspan="1">643</td><td align="center" valign="top" rowspan="1" colspan="1">506</td><td align="center" valign="top" rowspan="1" colspan="1">137</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Days on supplemental oxygen<sup><xref ref-type="table-fn" rid="TFN6">3</xref></sup> [median (IQR<sup><xref ref-type="table-fn" rid="TFN7">4</xref></sup>)]</td><td align="center" valign="top" rowspan="1" colspan="1">33 (10, 60)</td><td align="center" valign="top" rowspan="1" colspan="1">66 (39, 100)<sup><xref ref-type="table-fn" rid="TFN8">5</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">59 (31, 94)</td><td align="center" valign="top" rowspan="1" colspan="1">95 (68, 119)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Late-onset sepsis (+ culture) [(n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">75 (21)</td><td align="center" valign="top" rowspan="1" colspan="1">247 (38)</td><td align="center" valign="top" rowspan="1" colspan="1">171 (34)</td><td align="center" valign="top" rowspan="1" colspan="1">76 (55)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fungal sepsis [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">2 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (4)<sup><xref ref-type="table-fn" rid="TFN8">5</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">15<sup><xref ref-type="table-fn" rid="TFN8">5</xref></sup> (3.0)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (5.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Grade 3-4 intraventricular hemorrhage or periventricular leukomalacia [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">29 (8)</td><td align="center" valign="top" rowspan="1" colspan="1">98 (15)<sup><xref ref-type="table-fn" rid="TFN8">5</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">69<sup><xref ref-type="table-fn" rid="TFN8">5</xref></sup> (14)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (21)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Proven necrotizing enterocolitis<sup><xref ref-type="table-fn" rid="TFN9">6</xref></sup> [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">20 (6)</td><td align="center" valign="top" rowspan="1" colspan="1">72 (11)</td><td align="center" valign="top" rowspan="1" colspan="1">54 (11)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (13)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Patent ductus arteriosus (medical or surgical) [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">123 (35)</td><td align="center" valign="top" rowspan="1" colspan="1">365 (57)</td><td align="center" valign="top" rowspan="1" colspan="1">271 (54)</td><td align="center" valign="top" rowspan="1" colspan="1">94 (69)</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><label>1</label><p id="P30">Retinopathy of prematurity</p></fn><fn id="TFN5"><label>2</label><p id="P31">p&#x0003c;0.05 for all comparisons of No ROP vs Any ROP (mild, moderate, or severe)</p></fn><fn id="TFN6"><label>3</label><p id="P32">Tabulated until 120 days or discharge if discharged sooner, among infants who survived to discharge, transfer or 120 days</p></fn><fn id="TFN7"><label>4</label><p id="P33">Interquartile range</p></fn><fn id="TFN8"><label>5</label><p id="P34">Missing data for 1 infant</p></fn><fn id="TFN9"><label>6</label><p id="P35">Modified Bell's stage II or III<sup><xref rid="R26" ref-type="bibr">26</xref></sup></p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float" orientation="landscape"><label>Table 3</label><caption><p>Postmenstrual and chronological age of onset<sup><xref ref-type="table-fn" rid="TFN10">1</xref></sup> [with 95% confidence intervals (CI<sup><xref ref-type="table-fn" rid="TFN11">2</xref></sup>)] of any stage ROP<sup><xref ref-type="table-fn" rid="TFN12">3</xref></sup> (among infants with ROP age of onset determined)</p></caption><table frame="box" rules="all"><thead><tr><th colspan="2" align="left" valign="top" rowspan="1"/><th colspan="9" align="center" valign="top" rowspan="1">Cumulative Percent with Onset of ROP (by age of onset and ROP category)</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">ROP type</th><th align="center" valign="top" rowspan="1" colspan="1">n</th><th align="center" valign="top" rowspan="1" colspan="1">Min<sup><xref ref-type="table-fn" rid="TFN13">4</xref></sup></th><th align="center" valign="top" rowspan="1" colspan="1">1%</th><th align="center" valign="top" rowspan="1" colspan="1">5%</th><th align="center" valign="top" rowspan="1" colspan="1">25%</th><th align="center" valign="top" rowspan="1" colspan="1">50%</th><th align="center" valign="top" rowspan="1" colspan="1">75%</th><th align="center" valign="top" rowspan="1" colspan="1">95%</th><th align="center" valign="top" rowspan="1" colspan="1">99%</th><th align="center" valign="top" rowspan="1" colspan="1">Max<sup><xref ref-type="table-fn" rid="TFN13">4</xref></sup></th></tr></thead><tbody><tr><td colspan="2" align="left" valign="top" rowspan="1"/><td colspan="9" align="center" valign="top" rowspan="1">Postmenstrual Age (weeks)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Any ROP (95%CI)</td><td align="center" valign="top" rowspan="1" colspan="1">634</td><td align="center" valign="top" rowspan="1" colspan="1">29.3</td><td align="center" valign="top" rowspan="1" colspan="1">30.4 (29.6-30.7)</td><td align="center" valign="top" rowspan="1" colspan="1">31.4 (31.1-31.4)</td><td align="center" valign="top" rowspan="1" colspan="1">32.7 (32.4-32.9)</td><td align="center" valign="top" rowspan="1" colspan="1">33.9 (33.7-34.0)</td><td align="center" valign="top" rowspan="1" colspan="1">35.1 (34.9-35.4)</td><td align="center" valign="top" rowspan="1" colspan="1">38.0 (37.3-38.7)</td><td align="center" valign="top" rowspan="1" colspan="1">41.0 (39.9-43.6)</td><td align="center" valign="top" rowspan="1" colspan="1">46.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Type 2 ROP<sup><xref ref-type="table-fn" rid="TFN14">5</xref></sup> (95%CI)</td><td align="center" valign="top" rowspan="1" colspan="1">158</td><td align="center" valign="top" rowspan="1" colspan="1">29.3</td><td align="center" valign="top" rowspan="1" colspan="1">29.7 (29.3-30.7)</td><td align="center" valign="top" rowspan="1" colspan="1">31.1 (30.6-31.7)</td><td align="center" valign="top" rowspan="1" colspan="1">34.3 (33.6-34.9)</td><td align="center" valign="top" rowspan="1" colspan="1">36.1 (35.7-36.9)</td><td align="center" valign="top" rowspan="1" colspan="1">38.1 (37.6-38.7)</td><td align="center" valign="top" rowspan="1" colspan="1">40.4 (39.9-43.7)</td><td align="center" valign="top" rowspan="1" colspan="1">46.4 (43.3-46.9)</td><td align="center" valign="top" rowspan="1" colspan="1">46.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Severe (Type 1/treated) ROP (95% CI)</td><td align="center" valign="top" rowspan="1" colspan="1">128</td><td align="center" valign="top" rowspan="1" colspan="1">32.1</td><td align="center" valign="top" rowspan="1" colspan="1">32.7 (32.1-32.7)</td><td align="center" valign="top" rowspan="1" colspan="1">33.9 (32.7-34.3)</td><td align="center" valign="top" rowspan="1" colspan="1">35.1 (34.7-35.4)</td><td align="center" valign="top" rowspan="1" colspan="1">36.4 (35.7-36.9)</td><td align="center" valign="top" rowspan="1" colspan="1">38.6 (37.4-40.0)</td><td align="center" valign="top" rowspan="1" colspan="1">43.3 (41.0-45.0)</td><td align="center" valign="top" rowspan="1" colspan="1">45.0 (44.4-53.1)</td><td align="center" valign="top" rowspan="1" colspan="1">53.1</td></tr></tbody></table><table frame="box" rules="all"><thead><tr><th colspan="2" align="left" valign="top" rowspan="1"/><th colspan="9" align="center" valign="top" rowspan="1">Cumulative Percent with Onset of ROP (by age of onset and ROP category)</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">ROP type</th><th align="center" valign="top" rowspan="1" colspan="1">n</th><th align="center" valign="top" rowspan="1" colspan="1">Min</th><th align="center" valign="top" rowspan="1" colspan="1">1%</th><th align="center" valign="top" rowspan="1" colspan="1">5%</th><th align="center" valign="top" rowspan="1" colspan="1">25%</th><th align="center" valign="top" rowspan="1" colspan="1">50%</th><th align="center" valign="top" rowspan="1" colspan="1">75%</th><th align="center" valign="top" rowspan="1" colspan="1">95%</th><th align="center" valign="top" rowspan="1" colspan="1">99%</th><th align="center" valign="top" rowspan="1" colspan="1">Max</th></tr></thead><tbody><tr><td colspan="2" align="left" valign="top" rowspan="1"/><td colspan="9" align="center" valign="top" rowspan="1">Chronological Age (weeks)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Any ROP (95%CI)</td><td align="center" valign="top" rowspan="1" colspan="1">634</td><td align="center" valign="top" rowspan="1" colspan="1">4.0</td><td align="center" valign="top" rowspan="1" colspan="1">4.6 (4.1-4.7)</td><td align="center" valign="top" rowspan="1" colspan="1">5.4 (5.0-5.6)</td><td align="center" valign="top" rowspan="1" colspan="1">6.9 (6.6-6.9)</td><td align="center" valign="top" rowspan="1" colspan="1">8.0 (7.9-8.1)</td><td align="center" valign="top" rowspan="1" colspan="1">9.4 (9.1-9.6)</td><td align="center" valign="top" rowspan="1" colspan="1">11.9 (11.3-13.0)</td><td align="center" valign="top" rowspan="1" colspan="1">15.3 (14.4-18.0)</td><td align="center" valign="top" rowspan="1" colspan="1">19.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Type 2 ROP<sup><xref ref-type="table-fn" rid="TFN12">3</xref></sup> (95%CI)</td><td align="center" valign="top" rowspan="1" colspan="1">158</td><td align="center" valign="top" rowspan="1" colspan="1">4.4</td><td align="center" valign="top" rowspan="1" colspan="1">4.6 (4.4-5.6)</td><td align="center" valign="top" rowspan="1" colspan="1">6.3 (4.7-6.6)</td><td align="center" valign="top" rowspan="1" colspan="1">8.7 (7.9-9.6)</td><td align="center" valign="top" rowspan="1" colspan="1">10.8 (10.3-11.4)</td><td align="center" valign="top" rowspan="1" colspan="1">12.6 (12.0-13.1)</td><td align="center" valign="top" rowspan="1" colspan="1">15.0 (14.1-19.6)</td><td align="center" valign="top" rowspan="1" colspan="1">21.0 (17.0-22.7)</td><td align="center" valign="top" rowspan="1" colspan="1">22.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Severe (Type 1/treated) ROP (95% CI)</td><td align="center" valign="top" rowspan="1" colspan="1">128</td><td align="center" valign="top" rowspan="1" colspan="1">6.4</td><td align="center" valign="top" rowspan="1" colspan="1">7.1 (6.4-7.9)</td><td align="center" valign="top" rowspan="1" colspan="1">8.4 (7.1-8.9)</td><td align="center" valign="top" rowspan="1" colspan="1">9.8 (9.3-10.3)</td><td align="center" valign="top" rowspan="1" colspan="1">11.3 (10.6-11.7)</td><td align="center" valign="top" rowspan="1" colspan="1">13.1 (12.4-14.4)</td><td align="center" valign="top" rowspan="1" colspan="1">17.0 (16.1-19.0)</td><td align="center" valign="top" rowspan="1" colspan="1">19.0 (18.9-28.4)</td><td align="center" valign="top" rowspan="1" colspan="1">28.4</td></tr></tbody></table><table-wrap-foot><fn id="TFN10"><label>1</label><p id="P36">Age of onset is defined as the age at which the specified type of ROP was first observed while following the study monitoring protocol. For &#x0201c;Any ROP&#x0201d;, this is the first exam with any stage of ROP in any zone.</p></fn><fn id="TFN11"><label>2</label><p id="P37">Confidence interval</p></fn><fn id="TFN12"><label>3</label><p id="P38">Retinopathy of prematurity</p></fn><fn id="TFN13"><label>4</label><p id="P39">Min = minimum age at which designated severity of ROP was identified; max = maximum age.</p></fn><fn id="TFN14"><label>5</label><p id="P40">Type 2 ROP is defined as stage 3 in zone II, no plus disease or stage 1 or 2 in zone I, no plus disease. (85 of these infants had ROP that regressed and 73 infants later developed severe ROP.)</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Postmenstrual age of severe ROP<sup><xref ref-type="table-fn" rid="TFN15">1</xref></sup> onset and discharge for infants with severe ROP determined before and after discharge home</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Infants with Severe ROP N=137</th><th align="center" valign="top" rowspan="1" colspan="1">First exam with severe ROP occurred <underline>before</underline> discharge to home n=123</th><th align="center" valign="top" rowspan="1" colspan="1">First exam with severe ROP criteria occurred <underline>after</underline> discharge to home<sup><xref ref-type="table-fn" rid="TFN16">2</xref></sup> n=14</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Postmenstrual age at first occurrence of severe ROP: weeks [median, range]</td><td align="center" valign="top" rowspan="1" colspan="1">36.0 (32.1-45.0)</td><td align="center" valign="top" rowspan="1" colspan="1">40.9 (37.9-53.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Postmenstrual age at discharge: weeks [median, range]</td><td align="center" valign="top" rowspan="1" colspan="1">42.5 (37.7-78.3)</td><td align="center" valign="top" rowspan="1" colspan="1">38.3 (36.4-51.3)</td></tr></tbody></table><table-wrap-foot><fn id="TFN15"><label>1</label><p id="P41">Retinopathy of prematurity</p></fn><fn id="TFN16"><label>2</label><p id="P42">Among these 14 infants, 4 had been transferred back to lower acuity neonatal intensive care units prior to discharge home.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" position="float" orientation="portrait"><label>Table 5</label><caption><p>ROP<sup><xref ref-type="table-fn" rid="TFN17">1</xref></sup> exam (most recent) prior to discharge for infants with final ROP status determined after discharge home</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Worst findings in either or both eyes on last exam prior to discharge:</th><th align="center" valign="top" rowspan="1" colspan="1">Severe ROP Group N=14</th><th align="center" valign="top" rowspan="1" colspan="1">No Severe ROP Group N=535</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Vessels in zone I [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lowest zone of vessels=II and any stage ROP in any zone [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">196</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lowest zone of vessels=II and no ROP [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">126</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lowest zone of vessels=III and any stage ROP in any zone [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">81</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lowest zone of vessels=III and no ROP [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">121</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plus disease [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No exam prior to discharge [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unknown (missing or incomplete information on exam prior to discharge) [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr></tbody></table><table-wrap-foot><fn id="TFN17"><label>1</label><p id="P43">Retinopathy of prematurity</p></fn></table-wrap-foot></table-wrap><table-wrap id="T6" position="float" orientation="portrait"><label>Table 6</label><caption><p>Risk factors for ROP<sup><xref ref-type="table-fn" rid="TFN18">1</xref></sup> for infants with final ROP status determined after discharge home</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Risk Factor</th><th align="center" valign="top" rowspan="1" colspan="1">Severe ROP Group N=14</th><th align="center" valign="top" rowspan="1" colspan="1">No Severe ROP Group N=535</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Birth weight, g [mean (SD)]</td><td align="center" valign="top" rowspan="1" colspan="1">701 (103)</td><td align="center" valign="top" rowspan="1" colspan="1">872 (185)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GA<sup><xref ref-type="table-fn" rid="TFN19">2</xref></sup> at birth, wks [mean (SD)]</td><td align="center" valign="top" rowspan="1" colspan="1">25.7 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">26.4 (1.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Days on oxygen [mean (SD)]</td><td align="center" valign="top" rowspan="1" colspan="1">59 (27)</td><td align="center" valign="top" rowspan="1" colspan="1">47 (33)<sup><xref ref-type="table-fn" rid="TFN20">3</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Early onset sepsis [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">10 (2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Late onset sepsis [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">7 (50)</td><td align="center" valign="top" rowspan="1" colspan="1">148 (28)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fungal sepsis [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">1 (7)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (2)<sup><xref ref-type="table-fn" rid="TFN20">3</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Grade 3-4 intraventricular hemorrhage or periventricular leukomalacia [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">59 (11.1)<sup><xref ref-type="table-fn" rid="TFN20">3</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Proven necrotizing enterocolitis [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">1 (7)</td><td align="center" valign="top" rowspan="1" colspan="1">36 (7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Patent ductus arteriosus [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">11 (79)</td><td align="center" valign="top" rowspan="1" colspan="1">258 (48)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Discharge on oxygen [n (%)]</td><td align="center" valign="top" rowspan="1" colspan="1">2 (14)</td><td align="center" valign="top" rowspan="1" colspan="1">88 (16)</td></tr></tbody></table><table-wrap-foot><fn id="TFN18"><label>1</label><p id="P44">Retinopathy of prematurity</p></fn><fn id="TFN19"><label>2</label><p id="P45">Gestational age</p></fn><fn id="TFN20"><label>3</label><p id="P46">N=534 (1 missing)</p></fn></table-wrap-foot></table-wrap></floats-group></article>